Gabaergic drugs in the treatment of cerebellar ataxia and other motor disorders of the central nervous system

Gamma-Aminobutyric Acid (GABA): Biosynthesis, Medicinal Uses and Health Effects

Volumn , Issue , 2014, Pages 93-108

  Gazulla, José ^a   Ruiz Gazulla, Carlota ^b   Tintoré, María ^c  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c INSTITUTE OF ADVANCED CHEMISTRY OF CATALONIA IQAC CSIC   (Spain)

Author keywords

Cortical cerebellar atrophy; Diaphragmatic myoclonus; GABAergic drugs; Olivopontocerebellar atrophy; Progressive encephalomyelitis with rigidiy; Spinocerebellar atrophy

Indexed keywords

AMINO ACIDS; BRAIN; CELLS; NEURODEGENERATIVE DISEASES; NEURONS;

CORTICAL CEREBELLAR ATROPHY; DIAPHRAGMATIC MYOCLONUS; GABAERGIC; OLIVOPONTOCEREBELLAR ATROPHY; PROGRESSIVE ENCEPHALOMYELITIS WITH RIGIDIY; SPINOCEREBELLAR ATROPHY;

NEUROLOGY;

EID: 84926393834     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (70)

1. Albin RL, Gilman S. (1990) Autoradiographic localization of inhibitory and excitatory amino acid neurotransmitter receptors in human normal and olivopontocerebellar atrophy cerebellar cortex. Brain Res. 522: 37-45.
2. Aldo WF, van de Warrenburg BPC, Munneke M, van Geel WJA, Bloem BR, et al. (2006) CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia. Neurology 67: 474-479.
3. Bastian AJ, Thach WT. (2002) Structure and function of the cerebellum. In: Manto MU, Pandolfo M, editors. The cerebellum and its disorders. Cambridge: Cambridge University Press. 49-66.
4. 2-δ protein. J. Med. Chem. 48: 2294-2307.
5. Berciano J, Boesch S, Pérez-Ramos JM, Wenning GK (2006) Olivopontocerebellar atrophy: toward a better nosological definition. Mov. Disord. 10: 1607-1613.
6. Berciano J (1981) La nosología de la atrofia olivopontocerebelosa. Revisión crítica. Arch. Neurobiol. 44: 163-181.
7. Berciano J (2002) Multiple system atrophy and idiopathic late-onset cerebellar ataxia. In: Manto MU, Pandolfo M, editors. The cerebellum and its disorders. Cambridge: Cambridge University Press. 178-197.
8. Berciano J (1982) Olivopontocerebellar atrophy. A review of 117 cases. J. Neurol. Sci. 53: 253-272.
9. Botez MI, Young SN (2001) Biogenic amine metabolites and thiamine in cerebrospinal fluid in heredo-degenerative ataxias. Can. J. Neurol. Sci. 28: 134-140.
10. Brown P, Marsden CD (1999) The stiff man and stiff man plus syndromes. J. Neurol. 246: 648- 652.
11. Chattopadhyay S, Kriscenski-Perry E, Wenger DA, Pearce DA (2002) An autoantibody to GAD65 in sera of patients with juvenile neuronal ceroid lipofuscinosis. Neurology. 59: 1816-1817.
12. Colin F, Ris L, Godaux E (2002) Neuroanatomy of the cerebellum. In: Manto MU, Pandolfo M, editors. The cerebellum and its disorders. Cambridge: Cambridge University Press. 6-27.
13. Cooper JR, Bloom FE, Roth RH (2003) The biochemical basis of neuropharmacology. Oxford: Oxford University Press.
14. Eadie MJ (1991) Cerebello-olivary atrophy. In: Vinken PJ, Bruyn GW, Klawans HL, editors. Handbook of Clinical Neurology, volume 60. Amsterdam: Elsevier Science Publishers B.V. 569-573.
15. Frontali M, Jodice C (2002) Spinocerebellar ataxia type 6. In: Manto MU, Pandolfo M, editors. The cerebellum and its disorders. Cambridge: Cambridge University Press. 451-458.
16. Gazulla J, Benavente I, Capablo JL (2001) Encefalomielitis progresiva con rigidez. Aspectos clínicos, electrofisiológicos y tratamiento con gabapentina. Neurología 16: 85-88.
17. Gazulla J, Benavente I. (2002) Gangliosidosis GM2 del adulto: mejoría de la ataxia con fármacos GABAérgicos. Neurología. 17: 157-161.
18. Gazulla Abío J, Feijóo de Freixo M, Val Adán P, Benavente Aguilar I (2003) Aspectos clínicos y terapéuticos de las mioclonias diafragmáticas. Neurología. 18: 473-477.
19. Gazulla J, Errea JM, Benavente I, Tordesillas C (2004a) Treatment of ataxia in cortical cerebellar atrophy with the GABAergic drug gabapentin. A preliminary study. Eur. Neurol. 52: 7-11.
20. Gazulla J, Benavente I, Capablo JL (2004b) Actualización farmacológica de un caso de encefalomielitis progresiva con rigidez, con respuesta favorable a gabapentina. Neurología. 19 (8): 460-461.
21. Gazulla J, Benavente I (2005) Mejoría sintomática de la atrofia olivopontocerebelosa con gabapentina. Rev. Neurol. 40: 285-288
22. Gazulla J, Benavente I, Sarasa M (2006) Ataxia-telangiectasia del adulto. Observación clínica y terapéutica. Neurología. 21: 447-451.
23. Gazulla J, Benavente I (2007) Single-blind, placebo-controlled pilot study of pregabalin for ataxia in cortical cerebellar atrophy. Acta. Neurol. Scand. 116: 235-8.
24. Gazulla J, Tintoré M (2007a) The P/Q-Type Voltage-Dependent Calcium Channel as Pharmacological Target in Spinocerebellar Ataxia Type 6: Gabapentin and Pregabalin may be of Therapeutic Benefit. Medical Hypotheses. 687: 131-136.
25. Gazulla J, Tintoré M (2007b) The P/Q-Type Voltage-Dependent Calcium Channel: a Therapeutic Target in Spinocerebellar Ataxia type 6. Acta. Neurologica Scand. 115 (5): 356-363.
26. Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, St Laurent RT (1995) Benzodiazepine receptor binding in cerebellar degenerations studied with positron emission tomography. Ann Neurol. 38: 176-185.
27. Gilman S, Little R, Johanns J, Heumann M, Kluin KJ, Junck L, et al. (2000) Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy. Neurology. 55: 527-532.
28. Gong HC, Hang J, Kobler L, Li L, Su TZ (2001) Tissue-specific expression and gabapentin-binding properties of calcium channelα2δsubunit subtypes. J. Membrane Biol. 184: 35-43.
29. Gong HC, Hang J, Kobler L, Li L, Su TZ (2001) Tissue-specific expression and gabapentin-binding properties of calcium channel α2-δsubunit subtypes- J. Membrane Biol. 184: 35-43.
30. Higgins JJ, Harley-White J, Kopin IJ (1995) Low lumbar CSF concentrations of homovanilic acid in the autosomal dominant ataxias. J. Neurol. Neurosurg. Psychiatry. 58: 760.
31. Honnorat J, Saiz A, Giometto B, Vincent A, Brieva L, de Andrés C, et al. (2001) Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies. Arch. Neurol. 58: 225-230.
32. Howell DA, Lees AJ, Toghill PJ (1979) Spinal internuncial neurones in progressive encephalomyelitis with rigidity. J. Neurol. Neurosurg. Psychiatry. 42: 773-785.
33. Imbrici P, Jaffe S, Eunson LH, Davies NP, Herd C, Robertson R, et al. (2004) Dysfunction of the brain calcium channel Cav2.1 in absence epilepsy and episodic ataxia. Brain. 127: 2682-2692.
34. Ishida K, Mitoma H, Song S, Uchihara T, Inaba K, Eguchi S, et al. (1999) Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase. Ann. Neurol. 46: 263-267.
35. Kanazawa I, Kwak S, Sasaki H, Mizusawa H, Muramoto O, Yoshizawa K, et al. (1985) Studies on neurotransmitter markers and neuronal cell density in the cerebellar system in olivopontocerebellar atrophy and cortical cerebellar atrophy. J. Neurol. Sci. 71: 193-208.
36. Kang MG, Felix R, Campbell KP (2002) Long-term regulation of voltage-gated Ca2+ channels by gabapentin. FEBS Lett. 528: 177-182.
37. Kish SJ, Perry TL, Hornykiewicz O (1984) Benzodiazepine receptor binding in cerebellar cortex: observations in olivopontocerebellar atrophy. J. Neurochem. 42: 466-469.
38. Kuroda H, Ogawa N, Yamawaki Y, Nukina I, Ofuji T, Yamamoto M, et al. (1982) Cerebrospinal fluid GABA levels in various neurological and psychiatric diseases. J. Neurol. Neurosurg. Psychiatry. 45: 257-260.
39. Kuzniecky R, Ho S, Pan J, Martin R, Gilliam F, Faught E, et al. (2002) Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology. 58: 368-372.
40. Kwong WH, Chan WY, Lee KKH, Fan M, Yew DT (2000) Neurotransmitters, neuropeptides and calcium binding proteins in developing human cerebellum: a review. J. Histochem. 32: 521-534.
41. Manyam BV, Giacobini E, Ferraro TN, Hare TA (1990) Cerebrospinal fluid as a reflector of central cholinergic and amino acid neurotransmitter activity in cerebellar ataxia. Arch. Neurol. 47: 1194-1199.
42. Matsuyama Z, Wakamori M, Mori Y, Kawakami H, Nakamura S (1999) Direct alteration of the P/Q-type Ca 2+ channel property by polyglutamine expansion in spinocerebellar ataxia 6. J. Neurosci. 19 RC 14:1-5.
43. Miller RG, Moore D, Young LA, Armon C, Barohn RJ, Bromberg MB, Bryan WW, Gelinas DF, Mendoza MC, Neville HE, Parry GJ, Petajan JH, Ravits JM, Ringel SP, Ross MA (1996) Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology. 47: 1383-8.
44. Miller RG, Moore DH 2nd, Gelinas DF, Dronsky V, Mendoza M, Barohn RJ, Bryan W, Ravits J, Yuen E, Neville H, Ringel S, Bromberg M, Petajan J, Amato AA, Jackson C, Johnson W, Mandler R, Bosch P, Smith B, Graves M, Ross M, Sorenson EJ, Kelkar P, Parry G, Olney R (2001) Western ALS Study Group. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology. 56: 843-8.
45. Mugnaini E (2000) GABAergic inhibition in the cerebellar system. In: Martin DL, Olsen RW, editors. GABA in the Nervous System: the view at fifty years. Philadelphia: Lippincott, Williams & Wilkins. 383-407.
46. Nakamura K, Yoshida K, Miyakazi D, Morita H, Ikeda S (2009) Spinocerebellar ataxia type 6 (SCA 6): clinical pilot trial with gabapentin. J. Neurol. Sci. 278: 107-111.
47. Ogawa N, Kuroda H, Ota Z, Yamamoto M, Otsuki S (1982) Cerebrospinal fluid gamma-aminobutiric acid variations in cerebellar ataxia. Lancet. 2:215.
48. Olson WL, Gruenthal M, Mueller ME, Olson WH (1997) Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. Am. J. Med. 102: 60-66.
49. Oppenheimer DR (1982) Diseases of the basal ganglia, cerebellum and motor neurons. In: Adams JH, Corsellis JAN, Duchen LW, editors. Greenfields Neuropathology. London: Edward Arnold. 699-747.
50. Orozco G, Estrada R, Perry TL, Araña J, Fernández R, González-Quevedo A, et al. (1989) Dominantly inherited olivopontocerebellar atrophy from Eastern Cuba. Clinical, neuropathological, and biochemical findings. J. Neurol. Sci. 93: 37-50.
51. Ostergaard LH, Gram L, Dam M (1995) Potential antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. New York: Raven Press Ltd. 1057-1061.
52. Ottersen OP, Walberg F (2002) Neurotransmitters in the cerebellum. In: Manto MU, Pandolfo M, editors. The cerebellum and its disorders. Cambridge: Cambridge University Press. 38-48.
53. Ottersen OP (1993) Neurotransmitters in the cerebellum. Rev Neurol (Paris). 149: 629-636.
54. Pazos A, Pascual J (2008) Farmacología de los movimientos anormales. Fármacos antiespásticos. In: Flórez J, Armijo JA, Mediavilla A, editors. Farmacología Humana. Barcelona: Elsevier Masson. 607-627.
55. Perry TL, Kish SJ, Hansen S, Currier RD (1981) Neurotransmitter amino acids in dominantly inherited cerebellar disorders. Neurology. 31: 237-242.
56. Perry TL, Kish SJ, Hinton D, Hansen S, Becker LE, Gelfand EW (1984) Neurochemical abnormalities in a patient with ataxia-telangiectasia. Neurology. 34: 187-191.
57. Rinne JO, Burn DJ, Mathias CJ, Quinn NP, Marsden CD, Brooks DJ (1995) Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann. Neurol. 37: 568-573.
58. Saiz A, Arpa J, Sagasta A, Casamitjana R, Zarranz JJ, Tolosa E, et al. (1997) Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset diabetes mellitus, and polyendocrine autoimmunity. Neurology. 49: 1026-1030.
59. Schmitz-Hübsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 66: 1717-1720.
60. Stefani A, Spadoni F, Bernardi G (1998) Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacol. 37: 83-91.
61. Synofzik M, Gonzalez MA, Lourenco CM, Coutelier M, Haack TB, Rebelo A, Hannequin D, Strom TM, Prokisch H, Kernstock C, Durr A, Schöls L, Lima-Martínez MM, Farooq A, Schüle R, Stevanin G, Marques W Jr, Züchner S (2014) PNPLA6 mutations cause Boucher-Neuhäuser and Gordon Holmes syndromes as part of a broad neurodegenerative spectrum. Brain. 137: 69-77.
62. Tohgi H, Abe T, Hashiguchi K, Takahashi S, Nozaki Y, Kikuchi T (1991) A significant reduction of putative transmitter amino acids in cerebrospinal fluid of patients with Parkinsońs disease and spinocerebellar degeneraton. Neurosci. Letter. 126: 155-158.
63. Toru S, Murakoshi T, Ishikawa K, Saegusa H, Fujigasaki H, Uchihara T, et al. (2000) Spinocerebellar ataxia type 6 mutation alters P-type calcium channel function. J. Biol. Chem. 275: 10893-10898.
64. Trouillas P, Takayanagi T, Currier RD, Subramony SH, Wessel K, Bryer A, et al. (1997) International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. J. Neurol. Sci. 145: 205-211.
65. Trouillas P (1993) Bases théoriques et propositions pour une neuropharmacologie de ĺataxie cérébelleuse. Rev. Neurol. (Paris). 149: 637-646.
66. Tu P, Galvin JE, Baba M, Giasson B, Tomita T, Leight S, et al. (1998) Glial cytoplasmatic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-sinuclein. Ann. Neurol. 44: 415-422.
67. Vulliemoz S, Vanini G, Truffert A, Chizzolini C, Seeck M (2007) Epilepsy and cerebellar ataxia associated anti-glutamic acid decarboxylase antibodies. J. Neurol. Neurosurg Psychiatry. 78: 187-189.
68. Walkley SU, Baker HJ, Rattazzi MC, Haskins ME, Wu JY (1991) Neuroaxonal dystrophy in neuronal storage disorders: evidence for major GABAergic neuron involvement. J. Neurol. Sci. 104: 1-8.
69. Whitehouse PJ, Muramoto O, Troncoso JC, Kanazawa I (1986) Neurotransmitter receptors in olivopontocerebellar atrophy: an autoradiographic study. Neurology. 36: 193-197.
70. Whiteley AM, Swash M, Urich H (1976) Progressive encephalomyelitis with rigidity: its relation to subacute myoclonic spinal neuronitis and to the stiff man syndrome. Brain. 99: 27- 42.